Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20970301 | 0.90 | TLR7 (0.64) | TLR7TLR8 | |
| SCHEMBL19503122 | 0.90 | TLR7 (0.68) | TLR7TLR8 | |
| SCHEMBL19475350 | 0.85 | TLR7 (0.46) | TLR7TLR8 | |
| SCHEMBL21550207 | 0.85 | TLR7 (0.56) | TLR7TLR8 | |
| SCHEMBL21566214 | 0.81 | TLR7 (0.56) | TLR7TLR8 | |
| SCHEMBL21550176 | 0.79 | TLR7 (0.54) | TLR7TLR8 | |
| SCHEMBL30598831 | 0.79 | TLR7 (0.54) | TLR7TLR8 | |
| SCHEMBL19475365 | 0.79 | TLR7 (0.42) | TLR7TLR8 | |
| SCHEMBL26981115 | 0.79 | TLR7 (1.00) | TLR7TLR8 | |
| SCHEMBL21949601 | 0.78 | TLR7 (0.55) | TLR7TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109071535-B | NLRP3 modulators | 先天肿瘤免疫公司 | 2021-10-08 | — | — | CN | disclosed |
| US-11072612-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC. (US) | 2021-07-27 | — | — | US | disclosed |
| US-11072612-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC. (US) | 2021-07-27 | — | — | US | disclosed |
| US-20200157097-A1 | NLRP3 MODULATORS | INNATE TUMOR IMMUNITY INC (US) | 2020-05-21 | — | — | US | disclosed |
| US-20200157097-A1 | NLRP3 MODULATORS | INNATE TUMOR IMMUNITY INC (US) | 2020-05-21 | — | — | US | disclosed |
| US-10556903-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC. (US) | 2020-02-11 | — | — | US | disclosed |
| US-10556903-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC. (US) | 2020-02-11 | — | — | US | disclosed |
| US-20190127367-A1 | NLRP3 MODULATORS | INNATE TUMOR IMMUNITY INC (US) | 2019-05-02 | — | — | US | disclosed |
| US-20190127367-A1 | NLRP3 MODULATORS | INNATE TUMOR IMMUNITY INC (US) | 2019-05-02 | — | — | US | disclosed |
| WO-2017184746-A1 | NLRP3 MODULATORS | IFM THERAPEUTICS, INC (US) | 2017-10-26 | — | — | WO | disclosed |
| WO-2017184746-A1 | NLRP3 MODULATORS | IFM THERAPEUTICS, INC (US) | 2017-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11072612-B2 | NLRP3 modulators | NLRP3, NLRP1, NOD1 | TLR7 161/4885TLR8 196/4885 |
| US-20200157097-A1 | NLRP3 MODULATORS | NLRP3, NLRP1, NOD1 | TLR7 161/4885TLR8 196/4885 |
| US-10556903-B2 | NLRP3 modulators | NLRP3, NLRP1, NOD1 | TLR7 161/4885TLR8 196/4885 |
| US-20190127367-A1 | NLRP3 MODULATORS | NLRP3, NLRP1, NOD1 | TLR7 207/4885TLR8 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.